Jiangtao Yu

Jiangtao Yu is a Managing Director at Gaorong Ventures (高榕创投), where he works on the firm's healthcare investing — a practice covering new drug R&D and biotech platforms, medical devices and diagnostics, and digital health and medical services . He holds a PhD and has publicly represented the firm on its portfolio milestones: commenting on Alto Neuroscience's NYSE listing in February 2024, where he described how founder Amit Etkin's biomarker-based patient stratification could raise clinical success rates in psychiatric drug development and even revive previously failed candidates , and appearing alongside Zhenjiankang Medical's founder Zhang Haoren at the company's June 2026 Hong Kong IPO, billed as the first listed puncture surgical robot company . Beyond these deal-side appearances, elsewhere's corpus holds no deeper profile of his background or earlier career.